Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.75 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
6.50 7.00 6.75 6.75 6.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.77 -0.53 -0.16 26
Last Trade Time Trade Type Trade Size Trade Price Currency
15:40:57 O 10,000 6.98 GBX

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
04/4/202014:57Eden Research7,569
03/4/202018:10Eden Research; novel encapsulation and delivery technologies941
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3
18/5/201202:24Eden Research6

Add a New Thread

Eden Research (EDEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 6.75p.
Eden Research Plc has a 4 week average price of 4.65p and a 12 week average price of 4.65p.
The 1 year high share price is 11.50p while the 1 year low share price is currently 4.65p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 156,427 shares. The market capitalisation of Eden Research Plc is £25,672,965.46.
investingisatrickygame: wan Post #862"some of your rants!" I don't see it that way, but each to their own. I do 'go on' about and aim to back up where possible about 2 things 1) Eden's share price 2) Eden's communications Let's deal with number two In the last 2 years+, Eden has now moved on to its third PR Company. Walbrook, Powerscourt and now Hawthorn. That tells me two things. 1) Eden has an investor image problem. They are not understood, as reflected in the share price. We can example a lack of understanding in the recent challenge from mirandaj to me about Cedroz. Supersonico has also challenged mirandaj and you too have commented on the same. If Eden had communicated sufficiently on the subject, there would in theory, be no misunderstanding and the conversation on this BB would not have evolved. It could of course be that we all have terrible memories and that Eden has communicated clearly. That said, the four of us have debated it. The problem with this poor image is that the BB's, rightly so, become the image of the Company because it is the only place that is holding debate and seeking answers that are not provided by the Company. Therefore, a Company, today, has to take control of its own communications (which Eden chooses not to do) to ensure that that communicate at the deepest level of relevance to shareholders, so that they do understand, so that they can invest with confidence, so that these BB's do not become the image of the Company. Eden in my opinion, has yet to acknowledge this. 2)I know that Powerscourt was only charged with financial PR. So to be fair to Powerscourt, they had no remit to go beyond this and be more expansive about Eden. I believe this was the case with Walbrook too, event though they tried to get Eden to step forward. So we appear to have two consecutive PR firms, tied by Eden's apparent lack of share price ambition through communication to unravel the story and understanding properly for the benefit of the whole investor community. What remit has Hawthorn been given, do they want to follow the situation of their predecessors or are they just happy to receive their monthly fee and follow in the footsteps of the last two? Let us all hope the latter is not true. Personally, I do not think it reflects well on the Company for Eden to have 3 PR companies in such short time. I also do not think it reflects well on the Company to say they have no time to do communications because they area small staff base. To me, that is avoiding the elephant in the room. It is the single most important thing right now having Mevalone on sale in multiple countries, Cedroz going global, the Corteva deal and no doubt other global arrangements to soon follow. They have to get reflective value in the share price and they have to make time. They're possibly giving over a day to the forthcoming High Growth and Innovation day run by Shares Magazine. If so, they can certainly organise their time to deliver film which will be seen by many more people and create a library of news and communications to go back and look upon to cement ones understanding of Eden Research Plc. Share Price I do go on about the share price and this is because I do not think Eden is fairly valued at circa £18 million. If Eden was to come out and say within their communications that they are happy with their current market valuation and it reflects where they are in their corporate journey, so be it....but they don't. It is my opinion therefore that this needs addressing and the share price should be multiples of what it is today. To me, these are not rants, they are constructive opinion which is borne out be today's RNS and the depressing share price of today.
kenmitch: supersonico You’ve hit the nail on the head with your last question. If you are right Eden share price wil rocket! That’s why I still follow it, because you could be right. . BUT those massive gains won’t all come in 1 day. There could well be years where the share continues to rise as sales and profits soar year on year. Eden could even become a FTSE100 Company, and aside from the very start I’ll be in for that exciting ride. But I still can’t see the point of having my money tied up on this dream. I would rather miss the very beginning of the massive share price gains to come and invest again on genuine good news. Eden fans have been dreaming for so many years. It IS still right to dream because the promise of eventual success is still there, but there’s also the risk of it staying a dream for a lot longer.
investingisatrickygame: Morning wan, All very nice 'window dressing', but still, no one is looking in the window. The share price is further depressed and shows no intent to move upwards. I think we all understand in broad terms that Eden has good 'tech' and that being highly recommended reflects this. But, Eden management is in the business of operational execution to deliver success and this as a plc is most usually reflected in the share price. The share price shows no recognition of achievement whatsoever, does it?! Is Eden fairly valued at £16 million? Does that price in a global sales and distribution agreement with Eastman and the associated geographies for Sipcam with Mevalone? Does it price a fraction of the opportunity and possibility of Sustaine? Management remuneration continues to be high and their options price in a fraction of the opportunity and possibilities in the future for success. Remuneration packages at Eden and the Eden share price are not aligned, nor are the efforts towards the latter. I would like to see Eden fully recognise this and acknowledge the same and put some serious effort into turning the situation around. Trying and failing is one thing, but not really trying on the share price is another thing altogether. When you have such good remuneration packages you can afford for the share price to float around and underperform, but that may not be the case with your fellow shareholders, especially when they have invested in the promise land and been here for so long. It feels appropriate to me that Eden finally takes stock of this and apportions some of their working time to 'fixing' the share price for the benefit of all.
investingisatrickygame: Eden in summary R & D product X how many years Field trials X two seasons/years Regulatory approval X one year or up to Product sales and conversion/adoption X 2 years plus to gain trust and penetrate the market Possibly 5 years from field trials to meaningful revenue (when a product is not seasonally affected, like Mevalone, otherwise longer). Eden's share price 26p to 9p in 5 years when Eden HAS successfully gone through the above, so -60% We are told G3Y is entering the end (I believe) of season 2 trials, so maybe another 3 years before any meaningful revenue. Cedroz is known about, is a replacement product for Eastman and so should grab, hopefully, a natural market share. Regulatory approval is not yet secured, so maybe 2-3 years away. Brokers consistently WILL NOT factor in the next 3 years anticipated income for Eden. QUESTIONS What is it that management expects will drive the share price given the above? What is it that shareholders think will drive the share price given the above? Artemis has been a seller for a while as evidenced by the share register. When that overhang is gone, will the price rise a little or will another seller materialise? Even if the sellers are removed and the price rises, what is the first price point for exasperated shareholders to exit? Has Eden and its advisers planned for this? If so how? Who will step in again and mop up the sellers at that point? Eden in my opinion has an ongoing overhang whereby shareholders will sell into any rise that occurs because faith, time and more has them longing to remove themselves from the dire situation of the Eden share price. There are plenty of regulatory environments where share prices fly beforehand. Eden doesn't require huge capital to get of the ground, yet huge capital projects that do, still see there share price flying, knowing that is ahead of them, but because the asset base has risen. Eden excuses around regulatory environments doesn't hold water. It is wrong of them to say so and to say that shareholders don't understand when I'm sure that they do. Eden assets, in part, are its IP. 110 granted and pending patents we are told, but no value seems to be apportioned to these assets. Could that be because of the suggested timelines above? Personally, I feel that Eden makes too many excuses on third parties and process as their excuse for the share price and doesn't put enough emphasis on the forward value of the business and the solutions they deliver to the crop protection market which are much needed. their story is one of excuses and negativity, not one of reasons to invest and positivity. They do not open up the investment communities eyes to what they believe they will deliver. And, their emphasis continues to be institutions when Eden has a declining share price making Eden even less attractive and less able to invest in (Mcap). The resulting effect as we see is no demand for the company's shares, no belief in management as evidenced by the lack of buying and a flight elsewhere to greater visibility, expectation and potential reward.
investingisatrickygame: All of this focus on the future should be focused on the present. We, as shareholders, have been focused on the future for years. For how many more years are we going to say, the trend is from pesticides to biopesticides, when Eden gets in profit, let's wait and see what the interims say, let's wait and see what the full year-end figures are etc, etc, etc. The trend regarding pesticides to biopesticides, consumer opinion and demand and more is not the trend of the share price. Again, 26p in 2014 to 10p in 2019. Totally against the trend. Why is the Eden share price going against such a favourable trend and outlook? Why is management not kicking up a stink about this awkward share price trend? Why is management not adding to the BoD with someone who has an absolute focus on the share price and an ability to move the same? Why has Cenkos not bought one single share since their 'Killing It' report? How do Cenkos sales team on the back of that title encourage buyers when the share price target is just 12p? How does Eden management appear credible to investors given all of the above when they talk about their global ambitions and being just 'one of a few globally' etc, etc. Either management has to do something about the share price or maybe management needs new or/and replacement personnel to deliver the value that is so sadly lacking. These are the discussions investors should be having right now and not the blue sky and general industry discussions that are taking place. The share price reflects complacency and that is not good enough when you are a Plc, listed and with responsibilities to shareholders.
investingisatrickygame: Brucie 1. Not really relevant in a tech market, as long as its understood they will be coming in the years ahead 2. Massive credibility gap, I agree 3. Eden share price has dropped over 5 years and stayed at a low, so the present is not the reason 4. Maybe they will, but I think at 10/20p they will lose their investor base and credibility totally, so let's hope Cenkos has the wherewithal to lift the share price to 30/40p before that happens. Purely based on share price performance over the last 5 years, Eden is a dog of a share.
investingisatrickygame: PaulPaolo, post 6698 said "Have you not noticed that Eden is the most reticent of all firms about positives ? On balance, I do prefer this approach to the more showmanlike, untrustworthy (as I see it) CEOs of firms like Sound Energy, PANR, Kod and UKOG, who shout in RNS’s they “are delighted to announce good news” when there often seems to be none that’s real, and whose shares long term seem to turn out to be dogs." AND "Meantime, the poor comms compared to other AIM firms, keeps the shares cheap and I’ve gradually built up a good holding." Firstly, in my opinion, it is not about being "showmanlike", it is about behaving as a listed company should do or not be listed at all. Eden should shout about big news and enthuse and explain the same to encourage inward investment in the share price. If you are not going to do that then don't waste money with Proactive with dull and uninspiring interviews. Eden does have good news, does it not, but it makes very little effort to be truly expansive about its news and in turn convey a value proposition to those watching. So I do not see the comparisons you offer up as valuable when looking at Eden. It is also a mistake to be understated in my opinion and to not aid true and fair value into your share price You seem reasonably happy that communication is poor allowing to keep buying cheap shares. What about all of the long-term investors of say 10 years that are ripping their hair out because of Eden's ongoing inability to deliver true value into today's share price? I doubt they share your delight and rightly so. Let's see what price point Cenkos puts on Eden. I'll bet you it is much higher than Shore Capital and if so, the gap in value will look event bigger and management will look even poorer for that report, as will Eden's other advisers. The whole Eden share price is in my opinion, a disgrace and I know others think the same. I'm losing interest in the story, the application is undeniable, but value is all I seek now because it is value, or lack thereof, that has soured the story and that is something Eden will struggle to get away from.
investingisatrickygame: From Super's post, number 6400 hxxps:// The global market for biopesticides in 2019 is $6 billion From Eden's 2018 AGM presentation "Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation" Eden's market Cap is circa £22 million So which of the other 'few' global players has all the value & the sales? And what are their market caps? And how do they differ from Eden? It appears increasingly strange to me that Eden makes such statements and yet the divide between the statement and Eden's value is like a chasm. These things need better consideration and deeper explanation if people are to buy the Eden share price. In theory, based on Eden's statement and the 2019 market value then Eden should be priced at £'s, not pence. 'Professional' investors in the City have investment rules, will look for the onset of deep profits, dividends & more. Eden has thus far been unable to penetrate this market and Powerscourt have been unsuccessful in inducing that investment into Eden. Private investors don't have those rules, they look to get in early and cheap and they look for high capital growth and which point the 'professionals' step in and invest and the Pi's retreat, happy with their ROI. Eden still needs to address the latter and convince them to buy, something they continually demonstrate a lack of will to do
investingisatrickygame: I know a number of people are really fed up with the ongoing lack of value being reflected in the share price. I certainly am. How long, even in a regulatory framework, can one continue with the mantra that these things take time, especially when we have two commercial products, delivered via Sustaine, with Sustaine (we assume, not unreasonably) having successful trials elsewhere with Agrochemical majors and full confirmations still to come alongside commercial arrangements. Mevalone is now a global product as a result of Sipcam's uptake right's. It is, we are told, being used now as a pre-harvest, 'protector'/'insurer' against the possible later onset of Botrytis and it has post harvest viability too. Exempt from MRL & Generally Regarded As Safe (GRAS), Mevalone is the Natural Solution. From a marketing perspective, Eden and Powerscourt have everything to hand here except organic status. This story can run well either with the support of the press or stand alone using video and distribution partners to place in the right channels for understanding and word-of-mouth. Many people should be talking about Eden to the positive and it should create its own direction of travel. This is before we even address Cedroz which has a bigger impact, plus the awaited new products in bigger markets. You can take a definition from wherever you want, I've taken the easiest to find. "The chief executive officer (CEO)[1] or just chief executive (CE), is the most senior corporate, executive, or administrative officer in charge of managing an organization – especially an independent legal entity such as a company or nonprofit institution. CEOs lead a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (e.g., Crown corporations). The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price, market share, revenues or another element. In the non-profit and government sector, CEOs typically aim at achieving outcomes related to the organization's mission, such as reducing poverty, increasing literacy, etc. In the early 21st century, top executives typically had technical degrees in science, engineering or law.[2]" From above "The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price" I have no issue with Sean's online delivery, nor his connections, nor his IP knowledge and background. I have no basis to, I doubt anyone does. However, he is not maximising the share price. It cannot be argued one day Rodney, when so many days have passed with the result of the above products, relationships and technology. And we have a former high ranking employee of Bayer as our Chairman which doesn't on the face of it after 18 months in situ, appear to be delivering anything of value that we as shareholders can measure. That is fair observation. A CEO has to deliver share price value and that has to be on an ongoing basis, trending upwards and in line with business performance + forward prospects, traditionally measured on a three year timeline. Eden has nothing factored in for the latter and much of its business achievement thus far not factored in to today's share price. It is illogical and unrealistic to expect that one moment in time, yet to come, will catapult the share price north and vertical in an instant and correct all share price performance woes to-date. That if it ever happened, would lead to a mass sell out and a decline in the share price as quick as the incline that occurred. The CEO of Eden has to maximise the share price now and this is an ongoing role and responsibility. it isn't to be implemented when you wish to. It is an ongoing process. NDA's, partners et al do not have the power to supress another's share price and it is unthinkable to imagine this can be so. I know the BoD will read this and other posts and I know they will know who wrote this. I have no ill will towards the BoD, but our CEO whoever that may be an any point in time has to do their utmost to ensure that the share price of today and every day reflects the true value of the Company today. If they truly believe our share price and market cap is fair value right now, then do nothing at circa £23 million. If however this is not what they believe and know value to be, then they need to act to move the share price and show their audience true reasons why the share price should be much higher and therefore why people should invest in it today. This 'moan' by many is not going to go away until it is dealt with. Institutions are not and do not buy into Eden at this level. So they truly have no options but to stir up the market and in due course the hoped for institutions might come on board. Is our current CEO going to be the CEO to put value into the share price today based on current achievements or is another going to be brought into the business to deliver that value today, as well as the ongoing process of creating value for the future, the latter of which I am sure Sean is seeking to achieve.
investingisatrickygame: Eden, the Snail in the Garden I see Michael Walters has it spot on this time. There is a great deal of frustration around the Eden share price! The problem is that Eden is not allowed to tell common garden investors what is in the shore cap report even though as owners of the company we have paid for it via fees to the brokers! Fairly basic Proactive chats are no substitutions for real projections (that we all can see. Absence of proper broker support available to the private investor! Can the board come up with a new ay of marketing the shares? I have been posting the same on here for years, much to the frustration of some here and on other BB's, but it really is obvious. Perhaps Eden will now listen to Michael Walters. Eden has no traction in the City in regards to buying a position in Eden. Powerscourt who are meant to further the same have made no visible gains. Thus, the Shore Cap report is useless as it falls on deaf ears and a blind audience. They are not looking to see. An independent report by the likes of Edison or whomever similar would have far greater applicable reach to an audience with ears and eyes that will listen, namely the private investor. Furthermore, they are always looking for capital growth and are only restrained by the £ in their pocket, but they will buy and will buy quickly if the story adds up. Shore Caps clients will of course not respond the same. What is the market cap (oh they're too small), they're on AIM (no good), we do invest in green stocks, but none so young as Eden. The reason are extensive and an investment is often a far more complicated decision. Not so with the private investor. Eden does need to find a new way of marketing the shares, but in the first place they need TO MARKET THE SHARES. Eden do not market their shares and their toe in the water with Proactive is merely a series of process updates, albeit well explained, but they never give an investor a reason to buy and consequently, they don't. Eden must surely have learned its lesson over the last 2-3 years in regards to gaining investment in its share price, whom to target, why and how. Everything they have done, which is limited, has failed to incentivise people to invest, but then they have not targeted people (private investors). Eden sits at a market cap of circa £22 million. The narrative and the price still don't align It costs $25-$30 million to deliver a biopesticde to market, so $50-$60 million in total, almost three times our current market cap. The Chairman in the 2018 Annual Report says "the new products in the Company's pipeline aim to address markets which are potentially even bigger that those already covered by its existing products" Also he states " there is potential for an even greater opportunity around the use of Eden's proprietary, natural micro-encapsulation technology which is being teste by a number of third parties including some of the major agchem companies" Where is any of this in a three year forecast from the Company? How is this potential communicated to an investment public outside of this written word in the Annual Report. More importantly, how many people received a hard copy of the Annual Report and how many read/downloaded the PDF. Eden only talks to a few existing investors who are listening. The rest are asleep and the rest of their target audience has no idea who Eden is or the breakthroughs they are making. I very much doubt those not invested in Eden are reading our RNS's, why would they?! So MW is right, find a way to market Eden's shares to an audience that is willing to invest, willing to listen, available to listen and who equally importantly, will be your bag carrier of opportunity to other investors. In my opinion, if we sit here waiting for Powerscourt or a broker to unlock the door then Eden's shares will likely be dormant for some while to come. Finally and for Powerscourt, the world now seems to really understand that Pesticides are bad for you. Eat fruit, veg and nuts everyone; oh dear, they've been treated with pesticides, so maybe 5-a day is not as good for you as we suggested. Eden has a major PR opportunity right in the eye of the storm when readers will listen, journalists will listen and knock on Eden's door, doors will open for Powerscourt as a result of the same, the public will go to Eden's website to find out more, hey they might even invest. Why is Eden not challenging this when their share price is so low, their company value is so undervalued and the newspaper public, I'm sure, would love to hear about them. And it has nothing to do with a small employee base! Eden, one of only a few biocontrol companies globally with proven products and regulatory approval and yet, the investment world knows nothing about it!!!!!
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200404 16:30:23